Cochrane review: evidence too weak to support methadone for neuropathic pain
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Why this matters
- The evidence is too weak to draw conclusions about the value of methadone in treating neuropathic pain, according to a Cochrane review.
- The prevalence of neuropathic pain is 7%-10% of the general population, and it is difficult to treat.
- This was a systematic review of 3 randomized controlled trials (n=105) that met eligibility criteria after a search of CENTRAL, MEDLINE, EMBASE and 2 clinical trial registries.
- Funding: Saltonstall Fund for Pain Research; the National Institute for Health Research.
- The 3 trials had high risk for bias from incomplete recordi...